Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Comparison of the Safety and Comfort of AC-170

Phase: N/A Priority: Normal
NCT ID: NCT01495338 Org: User:
Start: 12/31/11 End: 12/31/11 Due: 12/31/12

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

Phase: N/A Priority: Normal
NCT ID: NCT02173249 Org: User:
Start: 06/30/14 End: 08/31/14 Due: 08/31/15

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Phase: N/A Priority: Normal
NCT ID: NCT02132169 Org: User:
Start: 05/31/14 End: 10/31/14 Due: 10/31/15

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

Phase: N/A Priority: Normal
NCT ID: NCT01134328 Org: User:
Start: 05/31/10 End: 07/31/10 Due: 07/31/11

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

Phase: N/A Priority: Normal
NCT ID: NCT01551056 Org: User:
Start: 03/31/12 End: 06/30/12 Due: 06/30/13

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Phase: N/A Priority: Normal
NCT ID: NCT01685242 Org: User:
Start: 09/30/12 End: 11/30/12 Due: 11/30/13

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Phase: N/A Priority: Normal
NCT ID: NCT01881113 Org: User:
Start: 06/30/13 End: 10/31/13 Due: 10/31/14

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

Phase: N/A Priority: Normal
NCT ID: NCT01332188 Org: User:
Start: 04/30/11 End: 10/31/11 Due: 10/31/12